These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Measles vaccine immunogenicity in 6- versus 15-month-old infants born to mothers in the measles vaccine era. Johnson CE, Nalin DR, Chui LW, Whitwell J, Marusyk RG, Kumar ML. Pediatrics; 1994 Jun; 93(6 Pt 1):939-44. PubMed ID: 8190581 [Abstract] [Full Text] [Related]
4. Immune response to measles vaccine in 6 month old infants in Papua New Guinea. Kurubi J, Vince J, Ripa P, Tefuarani N, Riddell M, Duke T. Trop Med Int Health; 2009 Feb; 14(2):167-73. PubMed ID: 19171008 [Abstract] [Full Text] [Related]
6. Follow-up of infants given measles vaccine at 6 months of age: antibody and CMI responses to MMRII at 15 months of age and antibody levels at 27 months of age. Carson MM, Spady DW, Beeler JA, Krezolek MP, Audet S, Pabst HF. Vaccine; 2005 May 09; 23(25):3247-55. PubMed ID: 15837229 [Abstract] [Full Text] [Related]
7. Waning antibody levels and avidity: implications for MMR vaccine-induced protection. Kontio M, Jokinen S, Paunio M, Peltola H, Davidkin I. J Infect Dis; 2012 Nov 15; 206(10):1542-8. PubMed ID: 22966129 [Abstract] [Full Text] [Related]
11. Early loss of passive measles antibody in infants of mothers with vaccine-induced immunity. Maldonado YA, Lawrence EC, DeHovitz R, Hartzell H, Albrecht P. Pediatrics; 1995 Sep 15; 96(3 Pt 1):447-50. PubMed ID: 7651776 [Abstract] [Full Text] [Related]
13. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. Lieberman JM, Williams WR, Miller JM, Black S, Shinefield H, Henderson F, Marchant CD, Werzberger A, Halperin S, Hartzel J, Klopfer S, Schödel F, Kuter BJ, Consistency Lot Study Group for ProQuad. Pediatr Infect Dis J; 2006 Jul 15; 25(7):615-22. PubMed ID: 16804432 [Abstract] [Full Text] [Related]
14. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine. Ovsyannikova IG, Pankratz VS, Vierkant RA, Jacobson RM, Poland GA. J Infect Dis; 2006 Mar 01; 193(5):655-63. PubMed ID: 16453260 [Abstract] [Full Text] [Related]
15. Measles-mumps-rubella and varicella vaccine responses in extremely preterm infants. D'Angio CT, Boohene PA, Mowrer A, Audet S, Menegus MA, Schmid DS, Beeler JA. Pediatrics; 2007 Mar 01; 119(3):e574-9. PubMed ID: 17332177 [Abstract] [Full Text] [Related]
16. Seroconversion after measles vaccination at nine and fifteen months of age. Işik N, Uzel N, Gökçay G, Kiliç A, Yilmaz G, Sadikoğlu B, Diri S. Pediatr Infect Dis J; 2003 Aug 01; 22(8):691-5. PubMed ID: 12913768 [Abstract] [Full Text] [Related]
17. Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults. Fiebelkorn AP, Coleman LA, Belongia EA, Freeman SK, York D, Bi D, Kulkarni A, Audet S, Mercader S, McGrew M, Hickman CJ, Bellini WJ, Shivakoti R, Griffin DE, Beeler J. J Infect Dis; 2016 Apr 01; 213(7):1115-23. PubMed ID: 26597262 [Abstract] [Full Text] [Related]
18. Antibody response after measles immunization. Ariyasriwatana C, Kalayanarooj S, Pattamadilok S. J Med Assoc Thai; 2003 Aug 01; 86 Suppl 3():S701-6. PubMed ID: 14700170 [Abstract] [Full Text] [Related]
19. Lidocaine-prilocaine patch decreases the pain associated with the subcutaneous administration of measles-mumps-rubella vaccine but does not adversely affect the antibody response. Halperin SA, McGrath P, Smith B, Houston T. J Pediatr; 2000 Jun 01; 136(6):789-94. PubMed ID: 10839878 [Abstract] [Full Text] [Related]
20. [The study of countermeasures on measles control in infants]. Wang L, Sun L, Jiang Z, Kang S, Liu Y, Jiang X. Zhonghua Liu Xing Bing Xue Za Zhi; 2001 Feb 01; 22(1):49-50. PubMed ID: 11860845 [Abstract] [Full Text] [Related] Page: [Next] [New Search]